Korean J Pediatr.
2008 Jan;51(1):73-77. 10.3345/kjp.2008.51.1.73.
Clinical significance of loss of p16 protein by immunohistochemical staining in acute lymphoblastic leukemia
- Affiliations
-
- 1Department of Pediatrics, College of Medicine, Chungnam National University, Daejeon, Korea. sunyoung@cnuh.co.kr
- 2Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon, Korea.
- 3Department of Clinical Laboratory Medicine, College of Medicine, Chungnam National University, Daejeon, Korea.
- 4Department of Pediatrics, Korea Cancer Center Hospital, Seoul, Korea.
- KMID: 1487162
- DOI: http://doi.org/10.3345/kjp.2008.51.1.73
Abstract
-
PURPOSE: p16 gene, mapped to the 9p21 chromosomal region, has emerged as a candidate tumor suppressor gene in human neoplasm. It is an inhibitor of cyclin-dependent kinase and inhibits Rb phosphorylation. In a variety of tumors including childhood acute lymphoblastic leukemia (ALL), deletion and/or mutation of the p16 gene has been found. Despite their high frequency, the prognostic importance of p16 alterations is still controversial in ALL and has been reported to be either unfavorable or similar to that of other patients. We studied the correlation between loss of p16 protein confirmed by immunohistochemical staining and clinical outcomes of patients diagnosed as ALL.
METHODS
We performed an immunohistochemical staining for p16 protein in 74 cases of bone marrow biopsy slide initially diagnosed as ALL between January 1998 and December 2006. We reviewed the clinical manifestations, laboratory findings, treatment outcomes retrospectively.
RESULTS
Of 74 slides, 12 were negative for p16 protein. Seven were males and 5 were females with a median age at diagnosis was 5.8 (1.3-18.8) years. Initial WBC were 17,225 (500-403,300)/microL. By immunologic surface marker analysis, 7 patients were early pre-B CALLA (+) and 5 patients were T-cell ALL. Two patients of intermediate risk group had relapsed and died. Three patients had family history of breast cancer. Four patients died and overall survival rates were 53.5+/-18.7%.
CONCLUSION
Loss of p16 protein is supposed to be an independent risk factor of childhood ALL associated with poor outcomes. In clinical setting, the clinician must take into account p16 status, not only at the genomic but also at the protein level. Further clinical experience on thoroughly investigated cases will help a better understanding between p16 status and clinical outcomes.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Pattern of p16 and pRb Expression in Acute Leukemia
- Precursor B-Cell Acute Lymphoblastic Leukemia in Two Patients with a History of Cytotoxic Therapy
- Mutational Analysis of CDKN2 (p16-INK4A/MTS1) Gene in Childhood Acute Leukemia
- Immunohistochemical Analysis of Abnormal p16INK4A Protein Expression in Human Breast Cancer
- p16 Deletion Fluorescence in situ Hybridization in Childhood Acute Lymphoblastic Leukemia
